Therapeutic Asset Ratings
4,361 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Vorinostat
Myelodysplastic Syndrome With Excess Blasts
National Cancer Institute (NCI)
P2
B
(62)
Hycamtin
Ovarian Clear Cell Adenocarcinoma
National Cancer Institute (NCI)
P2/3
B
(62)
Hycamtin
Ovarian Endometrioid Adenocarcinoma
National Cancer Institute (NCI)
P2/3
B
(62)
Inno-206
Fallopian Tube Endometrioid Adenocarcinoma
National Cancer Institute (NCI)
P2/3
B
(62)
Inno-206
Recurrent Primary Peritoneal Endometrioid Adenocarcinoma
National Cancer Institute (NCI)
P2/3
B
(62)
Nivolumab
Adenosquamous Lung Carcinoma
National Cancer Institute (NCI)
P2/3
B
(62)
Nivolumab
Infiltrating Bladder Urothelial Carcinoma
National Cancer Institute (NCI)
P2/3
B
(62)
Nivolumab
Muscle Invasive Ureter Urothelial Carcinoma
National Cancer Institute (NCI)
P2/3
B
(62)
Recombinant Human Hyaluronidase
Nodular Lymphocyte Predominant Hodgkin Lymphoma
National Cancer Institute (NCI)
P2/3
B
(62)
Relatlimab
Urinary Bladder Carcinoma
National Cancer Institute (NCI)
P2/3
B
(62)
Relatlimab
Renal Pelvis Urothelial Carcinoma
National Cancer Institute (NCI)
P2/3
B
(62)
Venetoclax
High Grade B-Cell Lymphoma With MYC And/ Or BCL2 And/Or BCL6 Rearrangement
National Cancer Institute (NCI)
P2/3
B
(62)
Cpx-351
Acute Myeloid Leukemia
National Cancer Institute (NCI)
P4
B
(61)
Atezolizumab
Melanoma
National Cancer Institute (NCI)
P3
B
(61)
Calcium folinate pentahydrate
Mixed Phenotype Acute Leukemia
National Cancer Institute (NCI)
P3
B
(61)
Docetaxel
Head And Neck Squamous Cell Carcinoma
National Cancer Institute (NCI)
P3
B
(61)
Eloxatin
Fallopian Tube Carcinoma
National Cancer Institute (NCI)
P3
B
(61)
FLUDEOXYGLUCOSE
Plasma Cell Myeloma
National Cancer Institute (NCI)
P3
B
(61)
FLUDEOXYGLUCOSE
Small Cell Lung Carcinoma
National Cancer Institute (NCI)
P3
B
(61)
Trastuzumab Deruxtecan
Non-Small Cell Lung Carcinoma
National Cancer Institute (NCI)
P3
B
(61)
Atezolizumab
Urinary Bladder Carcinoma
National Cancer Institute (NCI)
P2
B
(61)
azd6244
Pancreatic Ductal Adenocarcinoma
National Cancer Institute (NCI)
P2
B
(61)
azd6244
Refractory Malignant Neoplasm
National Cancer Institute (NCI)
P2
B
(61)
Busulphan
Hematopoietic And Lymphoid System Neoplasm
National Cancer Institute (NCI)
P2
B
(61)
Cediranib
Adult Alveolar Soft Part Sarcoma
National Cancer Institute (NCI)
P2
B
(61)
Showing 576 to 600 of 4,361 assets
Previous
Page 24 of 175
Next